文献速递生殖医学产科

微观模拟显示医学辅助生殖难以补偿女性生育年龄推迟导致的队列生育率下降

Microsimulation reveals that medically assisted reproduction is unlikely to compensate for cohort fertility decline due to increasing maternal ages.
PubMed 文献 · Hum Reprod · 2026-01-01

该研究用微观模拟模型模拟100万1974-1984年荷兰出生女性在同居关系内的生育历程,评估医学辅助生殖(MAR)对完成队列生育率(CCF)的补偿作用。结果显示,即使理想条件下MAR的净贡献仅为每名女性0.043个孩子,比观察到的MAR出生份额低33%,且在高龄段妊娠率下降等因素削弱其作用。结论认为MAR不太可能补偿因生育推迟导致的群体生育率下降。

要点

  • MAR净贡献为每名女性0.043个孩子,比观察到的MAR出生份额低33%
  • 增加MAR可及性(0%至100%)仅线性增加CCF 0.06个孩子
  • MAR相对贡献在35-39岁最强(6.0%),40岁及以上达8.6%

核心结论

  • 在1974-1984年荷兰出生女性样本中,MAR不太可能补偿因母亲年龄持续增加导致的同居关系内队列生育率下降,即使理想条件下也是如此。

研究设计与样本

  • 研究采用蒙特卡洛微观模拟模型,模拟100万名代表1974-1984年荷兰出生队列女性的生殖生命历程,输入参数样本量从数百到数十万不等,来源于调查、临床研究、面板数据和人口登记。

主要发现

  • MAR净贡献为每名女性0.043个孩子(占非MAR CCF的2.5%),比观察到的MAR出生份额(每名女性0.064个孩子,占模拟CCF的3.7%)低33%。
  • 将符合条件女性接受MAR的比例从0%增至100%可使CCF线性增加0.06个孩子。
  • 不孕诊断后等待ART治疗时间从1个月增至12个月使CCF降低0.01个孩子。
  • 报销IVF/ICSI周期数从0增至6使CCF增加0.05个孩子,增加在第2周期后放缓,第4周期后趋于平稳。
  • MAR相对贡献在35-39岁最强(6.0%),40岁及以上达8.6%,20-24岁为0%,25-29岁为1.0%;绝对数量贡献最大在30-34岁(0.016个孩子)和35-39岁(0.015个孩子)。

关键数值与推荐

  • 增加MAR最大女性年龄、开始IUI治疗时间及IUI周期数未明显增加CCF。
  • 开始MAR治疗的最小年龄在20-30岁之间时,政策杠杆调整带来的CCF变化模式几乎相同,而35岁和40岁时CCF水平及变化速率均降低。
  • CCF水平较低及变化速率较慢的主要影响因素包括高龄MAR妊娠率下降、随年龄增加的宫内死亡概率以及开始MAR前自然试孕时间。

临床怎么用

  • 临床应认识到MAR虽重要但不足以补偿群体生育率下降,需关注生育推迟的广泛影响。
  • 咨询时应考虑部分夫妇在更长期待管理下可能自然受孕,避免高估MAR对人口生育率的贡献。

局限性

  • 模型无法完全捕捉不孕诊断、伴侣特征和健康状况等生育及MAR过程的复杂性。
  • 由于信息缺失、参数众多及部分参数样本量有限,模型输出与参考数据略有偏差。
  • 因模型内生性无法确立因果关系。
  • 对IUI零贡献不完全确信,因临床数据提示IUI妊娠率高于期待管理但数据质量低且稀疏。
  • 研究范围限于同居关系内生育,因同居关系外生育信息不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Can medically assisted reproduction (MAR) compensate for completed cohort fertility (CCF) decline within coresidential unions due to increasing maternal ages among Dutch women born during 1974-1984? SUMMARY ANSWER: MAR is unlikely to compensate for cohort fertility decline within coresidential unions due to continued increase in maternal ages in our sample cohort of Dutch women born during 1974-1984, even under ideal conditions. WHAT IS KNOWN ALREADY: The pregnancy- and live birth rates for both expectant management and MAR decline at older reproductive ages. Some infertile couples can conceive naturally without undergoing treatment by trying to conceive for a longer period of time, which complicates estimating the contribution of MAR to cohort fertility. STUDY DESIGN, SIZE, DURATION: We developed a microsimulation model, which includes MAR, that simulates the reproductive life courses of women. We simulate a sample of 1 000 000 women representing the 1974-1984 Dutch birth cohort. Sample sizes for the input parameters varied from hundreds to thousands to hundreds of thousands depending on the parameter and source (surveys, clinical studies, panel data, population registers). PARTICIPANTS/MATERIALS, SETTING, METHOD: Our Monte Carlo microsimulation model uses probability distributions and parameters based on representative data sources to determine a woman's transitions through union and reproductive events across her reproductive life course. We assess the contribution of various components of the MAR process to CCF within coresidential unions and estimate the net contributions of MAR to CCF with counterfactual simulations. MAIN RESULTS AND THE ROLE OF CHANCE: Increases in the maximum female age at MAR treatment, the time to starting IUI treatment, and the number of IUI cycles did not noticeably increase CCF. Out of the hypothetical policy levers that were adjusted, increasing the share of eligible women who took up MAR from 0% to 100% increased CCF linearly by 0.06 children. Increasing the waiting time to ART treatment after infertility diagnosis from 1 to 12 months reduced CCF by 0.01. Increasing the number of reimbursed IVF/ICSI cycles from 0 to 6 increased CCF by 0.05. The increase tapered off after cycle number 2, and levelled off after cycle number 4. Minimum ages at which MAR treatment was started that were between 20 and 30 resulted in near-identical patterns of change in CCF from the adjustment in the potential policy levers, whereas both the CCF levels and rate of increase or decline were reduced at age 35 years, and further at age 40 years. The main influences on the lower CCF levels and slower rate or increase or decline were the reduction in MAR pregnancy rates at advanced reproductive ages, the increasing probability of intrauterine mortality with age, and time spent trying to conceive naturally before starting MAR treatment. The net contribution of MAR (0.043 children per woman, 2.5% to non-MAR CCF) was 33% smaller than the observed MAR birth share of CCF (0.064 children per woman, 3.7% of simulated CCF including MAR). The relative contribution of MAR was strongest at ages 35-39 (6.0%) and at age 40 years and above (8.6%), and weakest at ages 20-24 (0%) and 25-29 years (1.0%). In absolute number of children born, most of the contribution of MAR occurred at ages 30-34 (0.016 children) and ages 35-39 years (0.015). The Monte Carlo variation in the simulation model was measured to be around ±0.001 based on 10 simulations of 1 000 000 women. Parameter uncertainty was accounted for where possible by allowing parameters to vary within nonparametrically bootstrapped values generated from the sample data. LIMITATIONS, REASONS FOR CAUTION: Our model cannot fully capture the complexity of the fertility and MAR processes with regards to factors like infertility diagnosis, partner characteristics, and health status. Due to missing information, an extensive number of parameters, and limited sample sizes when estimating some of the parameters; the model output deviates slightly from the reference data. We cannot establish causality due to endogeneity in the modelling. We are not entirely confident in the zero contribution of IUI, because clinical data suggest that IUI pregnancy rates are higher than expectant management pregnancy rates, but the quality of that clinical data is low and sparse. The scope of the study is limited to births within coresidential unions, because information on unions and births outside of coresidential union was insufficient for modelling purposes. WIDER IMPLICATIONS OF THE FINDINGS: While MAR remains an important tool to address infertility, our results suggest that it is unlikely to compensate for population fertility decline attributable to postponement of childbearing to older reproductive ages. Failing to account for the counterfactual case that some couples who undergo MAR may conceive naturally given longer expectant management may lead to overestimation of the contribution MAR can make to population fertility. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by a VIDI grant (VI.Vidi.201.119) from the Netherlands Organization for Scientific Research to G.S. A.H. reports consulting fees by Ferring Pharmaceutical company The Netherlands, paid to institution UMCG, not related to the presented work. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Granholm R, Cantineau AEP, Hoek A, et al. Microsimulation reveals that medically assisted reproduction is unlikely to compensate for cohort fertility decline due to increasing maternal ages. Hum Reprod. 2026. PMID: 41704049. doi:10.1093/humrep/deag006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。